Basit öğe kaydını göster

Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.

dc.contributor.authorBaslar, Zafer
dc.contributor.authorErbilgin, Yücel
dc.contributor.authorAr, Muhlis Cem
dc.contributor.authorSuzan, Veysel
dc.contributor.authorElverdi, Tuğrul
dc.contributor.authorSalihoglu, Ayse
dc.contributor.authorSavci, Sercan
dc.contributor.authorSoysal, Teoman
dc.contributor.authorOngoren, Seniz
dc.contributor.authorBerk, Selin
dc.contributor.authorTuzuner, Nukhet
dc.contributor.authorEskazan, Ahmet Emre
dc.contributor.authorIseri, Sibel Aylin
dc.contributor.authorAydin, Yildiz
dc.contributor.authorOzbek, Ugur
dc.contributor.authorOzunal, Isil Erdogan
dc.contributor.authorYalniz, Fevzi Firat
dc.date.accessioned2021-03-06T08:36:10Z
dc.date.available2021-03-06T08:36:10Z
dc.date.issued2018
dc.identifier.citationOngoren S., Eskazan A. E. , Suzan V., Savci S., Ozunal I. E. , Berk S., Yalniz F. F. , Elverdi T., Salihoglu A., Erbilgin Y., et al., "Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.", Hematology (Amsterdam, Netherlands), cilt.23, ss.212-220, 2018
dc.identifier.issn1024-5332
dc.identifier.othervv_1032021
dc.identifier.otherav_e1b735f6-96e5-405d-aea1-ec1b3ad19662
dc.identifier.urihttp://hdl.handle.net/20.500.12627/148598
dc.identifier.urihttps://doi.org/10.1080/10245332.2017.1385193
dc.description.abstractObjectives: Newer tyrosine kinase inhibitors (TKIs) (bosutinib, ponatinib) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be utilized as a salvage therapy in patients with chronic myeloid leukemia (CML) who failed two lines (imatinib -> nilotinib or imatinib -> dasatinib) of TKI therapy. However, these TKIs are not available in many countries and not all patients can undergo allo-HSCT.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectHematoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectHEMATOLOJİ
dc.titleThird-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.
dc.typeMakale
dc.relation.journalHematology (Amsterdam, Netherlands)
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume23
dc.identifier.issue4
dc.identifier.startpage212
dc.identifier.endpage220
dc.contributor.firstauthorID89288


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster